Study on the Levels of the TPS in Serum, Pleural Effusion and BALF and Their Clinical Significance in Patients with Lung Cancer

LI Ya-li,ZHAO Li-qun,ZHANG Juan-ni,REN Xiao-xiao,ZHANG Jie,YANG de-chang

DOI: https://doi.org/10.3969/j.issn.1673-5269.2005.06.015

2005-01-01

Abstract:OBJECTIVE: This research detected tissue p ol ypeptide specificantigen (TPS)of serum, pleural effusion and BALF in lung cancer patients, according to the level of TPS, we can judge its clinical value to dia ngosea primary patients and to examine the histological typing and clinical peri od. METHODS: TPS was determined using enzyme immunoassay t echniques, we detected the TPS in 65 patients with lung cancer and compared with a group of 54 patients with some form of non-neoplastic pulmonary disease (NNP D). RESULTS: 1) The level of TPS of serum in lung cancer g roup is obvious higher than the matched control (P0.05); 2) In lung cancer group, the level of TPS in Pleural effusion is higher than serum and BALF; 3)Th e level of TPS in the NSCLC is higher than SCLC group; 4) The level of TPS in Ⅲ and Ⅳ period is higher thanⅠand Ⅱ period. CONSLUSION: 1)The TPS can identify the lung cancer from other lung disease. 2) The level of TPS in the serum and Pleural effusion is very stable, and can truely reflect the differentiation and and express of tumor. 3)TPS of serum and Pleural effusion c an distinguish NSCLC between SCLC.[